News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

KelpDAO attack causes $293 million DeFi losses
Cointurk·2026/05/16 13:57

3 Promising Altcoins to watch in 2026 — ZEC, DASH, and DOGE
Cryptonewsland·2026/05/16 13:42
Prediction Markets Emerge as Retail’s New Speculative ‘Toy,’ Barclays Says
CoinEdition·2026/05/16 13:39
Egrag Crypto: Fib Levels Are Revealing Entire Battlefield for XRP
TimesTabloid·2026/05/16 13:09
Pi Network (PI) Price Prediction: Will PI Reach $1?
BlockchainReporter·2026/05/16 13:00

Missed Bitcoin? IPO Genie Wants to Be Your Second Chance at the Next $3T Market
BlockchainReporter·2026/05/16 13:00
BNB hovers at $687 after sharp rally and ETF update
Cointurk·2026/05/16 12:39
Most of SWIFT’s Chosen Banks Already Running on Ripple (XRP). Here’s the Latest
TimesTabloid·2026/05/16 12:06
Crypto Market Cap Sees Modest Surge as Sentiment Remains Neutral
BlockchainReporter·2026/05/16 12:00
Microsoft Hit by $3.2 Billion Sell-Off From Bill Gates Foundation
BeInCrypto·2026/05/16 11:54
Flash
12:34
AngioDynamics announced that its Relief feasibility study, which aims to evaluate the Nanoknife irreversible electroporation (IRE) platform as a minimally invasive treatment option for benign prostatic hyperplasia (BPH), has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA).This approval marks a critical step for the company in expanding the application of its innovative technology. The Nanoknife IRE platform is designed to ablate targeted tissue with precision electric field energy while maximizing the protection of surrounding healthy structures. The Relief study for BPH will evaluate the safety and preliminary efficacy of this platform as a potential minimally invasive treatment option.Benign prostatic hyperplasia is a common, age-related male urinary system condition that can result in lower urinary tract symptoms, significantly affecting patients’ quality of life. Current standard treatments include medication and more invasive surgical procedures. If the study results are positive, Nanoknife IRE technology may offer patients a new treatment option that could be less traumatic.Obtaining IDE approval enables AngioDynamics to initiate patient recruitment for this clinical study in the United States. The study’s progress will be closely watched by the medical community and investors, as it may open new market opportunities for the company and validate the potential application of its technology platform in the urology field.
12:34
After the release of the U.S. May retail sales data, the U.S. Dollar Index rose slightly in the short term and is now reported at 99.64.US stock futures saw little short-term volatility, with Nasdaq 100 Index futures maintaining a gain of about 0.6%. The yield on the US 10-year Treasury bond showed little short-term fluctuation and is currently quoted at 4.440%. Spot gold experienced a slight short-term increase, currently quoted at $4327.37 per ounce.
12:34
Vivakor has successfully secured a one-year Bakken crude oil procurement deal, which is expected to bring the company approximately $115 million in annualized revenue.This transaction not only consolidates the company's market position in the energy sector, but also significantly enhances its short-term cash flow expectations. Market analysts believe that the signing of this contract demonstrates Vivakor's key role in the crude oil supply chain and may have a positive impact on its future stock price performance.
Trending news
MoreAfter the release of the U.S. May retail sales data, the U.S. Dollar Index rose slightly in the short term and is now reported at 99.64.
Vivakor has successfully secured a one-year Bakken crude oil procurement deal, which is expected to bring the company approximately $115 million in annualized revenue.